Probiotics as Potential Therapies in Human Gastrointestinal Health
Keywords:
Antibiotics induced ulcer, Bacterial translocation, PrebioticsAbstract
Nowadays, the treatment of gastrointestinal disorders with probiotics is a widely used remedy for intestinal complications in humans. This essential sources of microorganisms was originally developed for the treatment of health illness, based on the ability to functioning the normal pathway of intestine moreover, the clinical effects were reported as a remarkable advancement over commonly used treatment in GIT problems. Subsequently, it was realized that the clinical applicability of the enhanced intestinal floral development of used probiotics has been expanded to the therapeutic management of other gastrointestinal disorders, including cancer, heart failure etc.
References
1. Gibson GR, Roberfroid MB, Dietary
Modulation of the Human Colonic Microbiota.
Introducing the concept of prebiotics. J nutr
;125:1401-12.
Erika Isolauri, Yelda Sütas, Pasi Kankaanpää,
Heikki Arvilommi and Seppo Salminen
Probiotics: effects on immunity. American
Journal of Clinical Nutrition, Vol. 73, No.2,
S-450s, February 2001
Mailn M, Verronen P, Mykkanen H, et al.
Increased Bacterial Urease activity in faeces in
juvenile chronic arthritis: evidence of altread
intestinal microflora. Br j
rheumatol.1996;35:689-94.
Collins MD, et al. Reduces the risk of
antibiotic, allergic and infectious diarrhoea.
Am J Clin Nutr 1999;69(suppl):1052s-7s.
Fuller R, Probiotics in man and animals. J Appl
Bacteriol - 01-MAY-1989; 66(5): 365- 78.
Sanders ME, Considerations for use of
probiotic bacteria to modulate human health. J
nutr 2000; 130(2s suppl):384s-390s.
Mauro Cassaro, Massimo Rugge, et al.
Topographic Patterns of Intestinal Metaplasia
and Gastric Cancer. The American Journal of
Gastroenterology, Vol 95, No.6, 2000, pp
-8.
Glenn R. Gibson and Marcel B. Roberfroid
Dietary Modulation of the Human Colonic
Microbiota: Introducing the Concept of
Prebiotics. J. Nutr. 1995 125: 1401-1412
Wullt M, Hagslatt ML, Odenholt
I:Lactobacillus plantarum 299v for the
treatment of recurrent Clostridium difficileassociated diarrhoea: a double-blind, placebocontrolled trial. Scand J Infect Dis 2003,
:365-367.
McFarland LV, Surawicz CM, Greenberg RN,
et al.: A randomized placebo-controlled trial of
Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difficile
disease. JAMA 1994, 271:1913-1918
Adams M R, Hall C J, Growth inhibition of
food pathogens by lacticacid and acetic acid
and their mixtures. International journal of
food science & technology. Vol,23, issue 3,
pages 287-292.
Christine V. Salmond, Rohan G. Kroll, and Ian
R. Booth .The Effect of Food Preservatives on
pH Homeostasis in Escherichia coli.J Gen
Microbiol 1984 130: 2845-2850
14. Salminen S, Bouley C, Boutron Ruault
MC, Cummings JH, Franck A, Gibson
GR,Isolauri E, Moreau MC, Roberfroidm,
Rowland I. functional food science and
gastrointestinal physiology and function. Br J
Nutr , 1998,80(suppl 1):147-71.
Solauri E, Majamaa H, Arvola T, et al.
lactobacillus casei GG reverses increased
intestinal permeability induced by cow milk in
suckling rats. Gastroenterology,
;105:1643-50.
Mossman TR, Cherwinski H, Bond MW, et al.
Two types of murine helper T cell clone. I.
Definition according to profiles of lymphokine
activities and secreted proteins. J Immunol
; 136: 2348-57.
Perdigon G, de Macias N, Alvarez S, Oliver G,
de Ruiz Holgado AA. 1986. Effect on per
orally administered lactobacilli on macrophage
activity in mice. Infect. Immun. 53:404-10.
Perdigon G, de Macias N, Alvarez S, Oliver G,
de Ruiz Holgado AA. 1988. Systemic
augmentation of the immune response in mice
by feeding fermented milks with Lactobacillus
casei and Lactobacillus acidophilus.
Immunology. 63:17-23.
Sütas Y, Soppi E, Korhonen H, et al.
Suppression of lymphocyte proliferation in
vitro by bovine caseins hydrolysed with
Lactobacillus GG-derived enzymes. J Allergy
Clin Immunol 1996; 98:216-24
Sütas Y, Hurme M, Isolauri E. Scand J
Immunol. 1996 Jun;43(6):687-9.Down
regulation of anti-CD3 antibody-induced IL-4
production by bovine caseins hydrolysed with
Lactobacillus GG-derived enzymes.
Fedork N, Madsen KL, Probiotics and
Prebiotics in gastrointestinal disorders. Curr
opin gastroenterol 2004;20:149-55.
Isolauri E, Sutas Y, Kankaanpaa P, et al.
Probiotics: effect on immunity. Am j clin nutr
;73(suppl):444S-50S.
Hu FB, Stampfer MJ, Manson JE, Rimm EB,
Wolk A, Colditz GA, et al. Dietary intake of
alpha-linolenic acid and risk of fatal ischemic
heart disease among women.
McFarland LV, Surawicz CM, Greenberg RN,
et al.: A randomized placebo-controlled trial of
Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difficile
disease. JAMA 1994, 271:1913-1918.
Castagliuolo I, Lamont JT, Nikulasson ST, et
al. Saccharomyces boularidii protease inhibits
clostridium difficile toxin A effects in the rat
ileum. Infect immune 1996;64:5225-32.
Castagliuolo I, Riegler MF, Valenick L, et al.
Saccharomyces boularidii protects inhibits the
effects of clostridium difficille toxin a and b in
human colonic mucosa. Infect immune
;67:302-07.
Probiotics.Availableonhttp://www.probiotics.c
om/html/background/scientificsummary .html
.accessed on 08/12/2004
Lactobacillus acidophilus. Danone world
newsletter 1997:13(online) available on
http://www.danonevitapole.com assessed on
/12/2004
Dunne C, Shanhan F, Biotherapeutic agents in
the treatment of gasterointestinal disorders.
Current treatment options in infectious disease
; 5:183-88.
Blehaut H, Massot J, Elmer GW, et al.
Disposition kinetics of saccharomyces
boulardii in man and rat. Biopharm drug dispos
;104:353-64.
McFarland LV, Surawicz CM, Greenberg RN,
et al.: A randomized placebo-controlled trial of
Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difficile
disease. JAMA 1994, 271:1913-1918.
Brady LJ, Gallaher DD, Busta FF (February
. "The role of probiotic cultures in the
prevention of colon cancer". J. Nutr. 130 (2S
Suppl): 410S–414S
Rolfe, R. D. The Role of Probiotic Cultures in
the Control of Gastrointestinal Health. Journal
of Nutrition. 2000;130:396S-402S.)
Colum Dunne, Liam O'Mahony, Lisa Murphy,
Gerardine Thornton, Darrin Morrissey, Sile
O'Halloran, Maria Feeney, Sarah Flynn, Gerald
Fitzgerald, Charles Daly, Barry Kiely, Gerald
C O'Sullivan, Fergus Shanahan and J Kevin
Collins. In vitro selection criteria for probiotic
bacteria of human origin: Correlation with in
vivo findings. American Journal of Clinical
Nutrition, Vol. 73, No. 2, 386S-392s, February
Hamilton-Miller JM: The role of probiotics in
the treatment and prevention of Helicobacter
pylori infection. Int J Antimicrob Agents 2003,
:360-366.
Ushiyama A, Tanaka K, Aiba Y, et
al.:Lactobacillus gasseri OLL2716 as a
probiotic in clarithromycin-resistant
Helicobacter pylori infection. J Gastroenterol
Hepatol 2003, 18:986-991.
Cruchet S, Obregon MC, Salazar G, et al.:
Effect of the ingestion of a dietary product
containing Lactobacillus johnsonii La1 on
Helicobacter pylori colonization in children.
Nutrition 2003, 19:716-721.
Mukai T, Asasaka T, Sato E, et al.: Inhibition
of binding of Helicobacter pylori to the
glycolipid receptors by probiotic Lactobacillus
reuteri. FEMS Immunol Med Microbiol 2002,
:105-110.
McNaught CE, Woodcock NP, MacFie J, et al.:
A prospective randomised study of the
probiotic Lactobacillus plantarum 299V on
indices of gut barrier function in elective
surgical patients. Gut 2002, 51:827-831.
Sen S, Mullan MM, Parker TJ, et al.: Effect of
Lactobacillus plantarum 299v on colonic
fermentation and symptoms of irritable bowel
syndrome. Dig Dis Sci 2002, 47:2615-2620.
Gionchetti P, Amadini C, Rizzello F, et al.:
Probiotics for the treatment of postoperative
complications following intestinal surgery.
Best Pract Res Clin Gastroenterol 2003,
:821-831.
Rayes N, Seehofer D, Muller AR, et al.:
[Influence of probiotics and fibre on the
incidence of bacterial infections following
major abdominal surgery- results of a
prospective trial]. Z Gastroenterol 2002,
:869-876
Gary W. Elmer, PhD; Christina M. Surawicz,
MD; Lynne V. McFarland, PhD , A Neglected
Modality for the Treatment and Prevention of
Selected Intestinal and Vaginal Infections
.JAMA. 1996;275(11):870-876.
Akyol S, Mas MR, Comert B, et al.: The
effect of antibiotic and probiotic combination
therapy on secondary pancreatic infections and
oxidative stress parameters in experimental
acute necrotizing pancreatitis. Pancreas 2003,
:363-367.
Guandalini S, Pensabene L, Zikri MA, et
al.:Lactobacillus GG administered in oral
rehydration solution to children with acute
diarrhea: a multicenter European trial. J Pediatr
Gastroenterol Nutr 2000, 30:54-60.
Surawicz CM: Probiotics, antibiotic-associated
diarrhoea and Clostridium difficile diarrhoea in
humans. Best Pract Res Clin Gastroenterol
, 17:775- 783.
Kelleher SL, Casas I, Carbajal N, et al.:
Supplementation of infant formula with the
probiotic Lactobacillus reuteri and zinc: impact
on enteric infection and nutrition in infant
rhesus monkeys. J Pediatr Gastroenterol Nutr
, 35:162-168.
McFarland LV, Surawicz CM, Greenberg RN,
et al.: A randomized placebo-controlled trial of
Saccharomyces boulardii in combination with
standard antibiotics for Clostridium difficile
disease. JAMA 1994, 271:1913-1918.
Isolauri E: Probiotics for infectious diarrhoea.
Gut 2003, 52:436-437
50. Huang JS, Bousvaros A, Lee JW, et al.:
Efficacy of probiotic use in acute diarrhea
in children: a meta-analysis. Dig Dis Sci 2002,
:2625-2634.
Sambol SP, Merrigan MM, Tang JK, et al.:
Colonization for the prevention of
Clostridium difficile disease in hamsters. J
Infect Dis 2002, 186:1781-1789.
Cremonini F, Di Caro S, Nista EC, et al.: Metaanalysis: the effect of probiotic
administration on antibiotic-associated
diarrhoea. Aliment Pharmacol Ther 2002,
:1461-1467.
D'Souza AL, Rajkumar C, Cooke J, et al.:
Probiotics in prevention of antibiotic
associated diarrhoea: meta-analysis. BMJ 2002,
:1361.
Ahuja MC, Khamar B: Antibiotic associated
diarrhoea: a controlled study comparing plain
antibiotic with those containing protected
lactobacilli. J Indian Med Assoc 2002,
:334-335.
Sullivan A, Barkholt L, Nord CE:Lactobacillus
acidophilus, Bifidobacterium lactis and
Lactobacillus F19 prevent antibiotic-associated
ecological disturbances of Bacteroides fragilis
in the intestine. J Antimicrob Chemother 2003,
:308-311
Payne S, Gibson G, Wynne A, et al.:In vitro
studies on colonization resistance of the human
gut microbiota to Candida albicans and the
effects of tetracycline and Lactobacillus
plantarum LPK. Curr Issues Intest Microbiol
, 4:1-8.
Kim HJ, Camilleri M, McKinzie S, et al.: A
randomized controlled trial of a probiotic,
VSL#3, on gut transit and symptoms in
diarrhoea-predominant irritable bowel
syndrome. Aliment Pharmacol Ther 2003,
:895-904.
Costa-Ribeiro H, Ribeiro TC, Mattos AP, et
al.: Limitations of probiotic therapy in acute,
severe dehydrating diarrhea. J Pediatr
Gastroenterol Nutr 2003, 36:112-115.
Brigidi P, Vitali B, Swennen E, et al.: Effects
of probiotic administration upon the
composition and enzymatic activity of human
fecal microbiota in patients with irritable bowel
syndrome or functional diarrhea. Res Microbiol
, 152:735-741.
Femia AP, Luceri C, Dolara P, et al.:
Antitumorigenic activity of the prebiotic inulin
enriched with oligofructose in combination
with the probiotics Lactobacillus rhamnosus
and Bifidobacterium lactis on azoxymethaneinduced colon carcinogenesis in rats.
Carcinogenesis 2002, 23:1953-1960.
Sen S, Mullan MM, Parker TJ, et al.: Effects of
Lactobacillus plantarum 299v on symptoms
and colonic fermentation in irritable bowel
syndrome (IBS). Gut 2001, 48(suppl 1):A57.
O'Sullivan MA, O'Morain CA: Bacterial
supplementation in the irritable bowel
syndrome. A randomised double-blind
placebo-controlled crossover study. Dig Liver
Dis 2000, 32:294-301.
Nobaek S, Johansson ML, Molin G, et al.:
Alteration of intestinal microflora is associated
with reduction in abdominal bloating and pain
in patients with irritable bowel syndrome. Am J
Gastroenterol 2000, 95:1231-1238.
Niedzielin K, Kordecki H, Kosik R: New
possibility in the treatment of irritable bowel
syndrome: probiotics as a modification of the
microflora of the colon. Gastroenterology
, 114:A402.
Bauer TM, Fernandez J, Navasa M, et al.:
Failure of Lactobacillus spp. to prevent
bacterial translocation in a rat model of
experimental cirrhosis. J Hepatol 2002, 36:501-
Tamboli CP, Caucheteux C, Cortot A, et al.:
Probiotics in inflammatory bowel disease: a
critical review. Best Pract Res Clin
Gastroenterol 2003, 17:805-820.
Hart AL, Stagg AJ, Kamm MA: Use of
probiotics in the treatment of inflammatory
bowel disease. J Clin Gastroenterol 2003,
:111-119.
Gionchetti P, Amadini C, Rizzello F, et al.:
Probiotics-role in inflammatory bowel disease.
Dig Liver Dis 2002, 34(suppl 2):S58-S62.
Bamba T, Kanauchi O, Andoh A, et al.: A new
prebiotic from germinated barley for
nutraceutical treatment of ulcerative colitis. J
Gastroenterol Hepatol 2002, 17:818-824.
Kanauchi O, Serizawa I, Araki Y, et al.:
Germinated barley foodstuff, a prebiotic
product, ameliorates inflammation of colitis
through modulation of the enteric environment.
J Gastroenterol 2003, 38:134-141.
Ishikawa H, Akedo I, Umesaki Y, et al.:
Randomized controlled trial of the effect of
bifidobacteria-fermented milk on ulcerative
colitis. J Am Coll Nutr 2003, 22:56-63.
Marteau PR, de Vrese M, Cellier CJ,
Schrezenmeir J. Protection from
gastrointestinal diseases with the use of
probiotics. Am J Clin Nutr 2001;73:430S–6S
Gan BS, Kim J, Reid G, et al.:Lactobacillus
fermentum RC-14 inhibits Staphylococcus
aureus infection of surgical implants in rats. J
Infect Dis 2002, 185:1369-1372.
Kecskes G, Belagyi T, Olah A: [Early jejunal
nutrition with combined pre- and probiotics in
acute pancreatitis-prospective, randomized,
double-blind investigations]. Magy Seb 2003,
:3-8.
Mangiante G, Colucci G, Canepari P, et
al.:Lactobacillus plantarum reduces infection
of pancreatic necrosis in experimental acute
pancreatitis. Dig Surg 2001, 18:47-50.
Delia P, Sansotta G, Donato V, et al.:
Prevention of radiation-induced diarrhea with
the use of VSL#3, a new high-potency
probiotic preparation. Am J Gastroenterol
, 97:2150-2152.
Li Z, Yang S, Lin H, et al.: Probiotics and
antibodies to TNF inhibit inflammatory activity
and improve nonalcoholic fatty liver disease.
Hepatology 2003, 37:343-350.
Solga SF: Probiotics can treat hepatic
encephalopathy. Med Hypotheses 2003,
:307-313.
Borody TJ, Warren EF, Leis S, et al.:
Treatment of ulcerative colitis using fecal
bacteriotherapy. J Clin Gastroenterol 2003,
:42-47.
Seksik P, Rigottier-Gois L, Gramet G, et al.:
Alterations of the dominant faecal bacterial
groups in patients with Crohn's disease of the
colon. Gut 2003, 52:237-242.
Guandalini S: Use of Lactobacillus-GG in
paediatric Crohn's disease. Dig Liver Dis 2002,
(suppl 2):S63-S65.
Gionchetti P, Rizzello F, Venturi A, et al.:
Antibiotic combination therapy in patients with
chronic, treatment-resistant pouchitis. Aliment
Pharmacol Ther 1999, 13:713-718.
Gionchetti P, Rizzello F, Helwig U, et al.:
Prophylaxis of pouchitis onset with probiotic
therapy: a double-blind, placebo-controlled
trial. Gastroenterology 2003, 124:1202-1209.
Cremonini F, Di Caro S, Covino M, et al.:
Effect of different probiotic preparations on
anti-Helicobacter pylori therapy-related side
effects: a parallel group, triple blind, placebocontrolled study. Am J Gastroenterol 2002,
:2744-2749.
Rafter J: Probiotics and colon cancer. Best
Pract Res Clin Gastroenterol 2003, 17:849-859.
Rafter J: Lactic acid bacteria and cancer:
mechanistic perspective. Br J Nutr 2002,
(suppl 1):S89-S94.
Brady LJ, Gallaher DD, Busta FF (February
. "The role of probiotic cultures in the
prevention of colon cancer". J. Nutr. 130 (2S
Suppl): 410S–414S
Obermeier F, Dunger N, Strauch UG, et al.:
Contrasting activity of cytosin-guanosin
dinucleotide oligonucleotides in mice with
experimental colitis. Clin Exp Immunol 2003,
:217-224.
Kalliomaki M, Salminen S, Poussa T, et al.:
Probiotics and prevention of atopic disease: 4-
year follow-up of a randomised placebocontrolled trial. Lancet 2003, 361:1869-1871.
Kirjavainen PV, Salminen SJ, Isolauri E:
Probiotic bacteria in the management of atopic
disease: underscoring the importance of
viability. J Pediatr Gastroenterol Nutr 2003,
:223-227.
Saavedra J, Probiotics and infectious
diarrhea.Am J Gastroenterol
;95(Suppl):S8-S18
McCarthy M, Breaking up the bacterial happy
home.Lancet 2001;23:357(9373):2032-2033
Kuisma J, Mentula S, Jarvinen H, et al.: Effect
of Lactobacillus rhamnosus GG on ileal pouch
inflammation and microbial flora. Aliment
Pharmacol Ther 2003, 17:509-515.
Borriello SP, Hammes WP, Holzapfel W, et
al.: Safety of probiotics that contain lactobacilli
or bifidobacteria. Clin Infect Dis 2003, 36:775-
Isolauri E, Kirjavainen PV, Salminen S:
Probiotics: a role in the treatment of intestinal
infection and inflammation? Gut 2002,
(suppl 3):III54-III59.
Riquelme AJ, Calvo MA, Guzman AM, et
al.:Saccharomyces cerevisiae fungemia after
Saccharomyces boulardii treatment in
immunocompromised patients. J Clin
Gastroenterol 2003, 36:41-43.
Collins MD, et al. Reduces the risk of
antibiotic, allergic and infectious diarrhoea.
Am J Clin Nutr 1999; 69(suppl):1052s-7s. 153-
